Among the patients with baseline IR, part of the lipid profile including Apo AI and HDL levels increased and part of glucose profile including HOMA-IR, C-peptide and HbA1c levels decreased significantly after viral clearance. The prevalences of G1 CHC increased with age, while that of G2 CHC decreased with age. However, in the (-)-Maackiain current and other studies enrolled CHC patients consecutively, except pre-treatment HCV RNA, no other baseline characteristics, including age, were different between the G1 and G2 patients. Besides, in white patients with G1 CHC, the favorable IL28B rs12979860 CC genotype is associated with less pronounced disturbances in lipid metabolism and with reduced IR. In the current study, however, over 90% of the CHC patients with SVR had favorable IL-28B genotype regardless of HCV genotype. Therefore, host factors were less likely to explain the various metabolic Eupalinolide-B alterations in the G1 and G2 patients after viral clearance. The HCV core Ag is strongly associated with serum lipoviral particles. However, it did not correlate with any of the pre-treatment lipid profile items. Individual variation might account for this discrepancy. This observation highlights the importance of examining the changes in the lipid profiles after SVR in the same individuals. The current study demonstrates that G2 clearance affected the lipid profile more favorably than clearing G1 HCV did. Apart from TC, LDL, TG, and Apo B, G2 HCV clearance also increased the HDL and Apo AI levels, while G1 viral clearance increased the TG/HDL ratios. After SVR, the G1 patients had higher post-treatment TG levels and TG/HDL ratios than the G2 CHC patients. These genotype-specific impacts on metabolic profiles were even more evident after eliminating the influence of IR, as G1 but not G2 had increased post-therapeutic TG and HOMA-IR levels. Because high TG, low HDL levels and high TG/HDL ratios all indicate a metabolic syndrome, a cluster of cardiovascular risk factors due to IR, the worse metabolic profile after SVR might potentially lead to higher cardiovascular risks in G1 patients, as compared with G2 patients. This distinct pattern of lipid alterations between the G1 and G2 CHC patients after SVR is particularly important in areas like Taiwan, where most HCV infections are either G1 or G2.